Inotiv, Inc. · NASDAQ:NOTV
Inotiv — Bioanalytical Systems — IPO Roadshow (March 2011)
23 slides from Inotiv's IPO roadshow presentation, Mar 18, 2011
Slide 1: Investor Presentation – March 2011
Filed Pursuant to Rule 433 Registration No. 333-172508 March 18, 2011 Investor Presentation – March 2011
Slide 2: Safe Harbor Statement
Safe Harbor Statement MATTERS DISCUSSED IN THIS PRESENTATION CONTAIN FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. WHEN USED IN THIS DOCUMENT, THE WORDS "ANTICIPATE," "BELIEVE," "ESTIMATE, " "MAY," "INTEND, " "EXPECT " AND SIMILAR EXPRESSIONS
Slide 3: Transaction Summary Company Overview Facilities Overview Industry Overview Industry Overview – Growth Drivers Major
Transaction Summary Company Overview Facilities Overview Industry Overview Industry Overview – Growth Drivers Major Customers
Slide 4: Transaction Summary
Transaction Summary Bioanalytical Systems Inc. (NASDAQ:BASI) Issuer: Bioanalytical Systems, Inc. (“BASi”) Exchange / Stock Symbol: NASDAQ: BASI Industry: Health Care Services: Contract Research Services and Products Type of Offering / Gross Proceeds: Registered Securities Offering of $5.0 million Se
Slide 5: Company Overview
Company Overview Bioanalytical Systems, Inc. provides contract drug development services and research equipment to leading global pharmaceutical, medical research and biotechnology companies and institutions . The Company offers an efficient, variable -cost alternative to its clients' internal produ
Slide 6: Facilities Overview
Facilities Overview BASi’s state of the art facilities located in the U.S. and Europe provide clients with fast, reliable, and precise clinical research studies that are quality assured and compliant with federal guidelines . Facilities Overview Site Space (ft²) Business Units West Lafayette, IN 115
Slide 7: Industry Overview – Growth Drivers
Industry Overview – Growth Drivers The American CRO market generated more than $10 billion in revenue in 2009 and is expected to reach $30 billion by 2015, according to equity research by Jeffries & Company, Inc. American CRO Market Estimates: (2009 – 2015) $35.0 $30.0 $30.0 $25.0 illion $20.0 b $15
Slide 8: Major Customers
Major Customers Principal clients are pharmaceutical development managers engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic neuroscience research from small start-up biotechnology companies to many of the largest global phar
Slide 9: Drug Discovery and Development
Drug Discovery and Development Business Segments ]Contract Research Services Contract Research Services – BASi’s Advantage Business Segments -Research Products Scientific and Professional Depth BASi’s Focus and Strategy
Slide 10: Drug Discovery and Development
Drug Discovery and Development Bioanalytical Systems Inc. (NASDAQ:BASI) Page 10
Slide 11: Business Segments - Contract Research Services
Business Segments -Contract Research Services BASi’s Contract Research Services segment provides screening and pharmacological testing, nonclinical safety evaluation, pharmaceutical testing, regulatory compliance and quality control testing for drug developers . Non Clinical and Pathology Services –
Slide 12: Contract Research Services – BASi's Advantage
Contract Research Services – BASi’s Advantage In implementing its strategy to provide a service to its customers early in the drug discovery phase and work with the company to realize their milestones, BASi has created unique service offerings that capitalize on its internal expertise in services an
Slide 13: Research Products
Research Products BASi’s products business is focused on expediting preclinical screening of developmental drugs. BASi develops, manufactures and markets state-of-the-art In Vivo sampling systems and accessories, physiology monitoring tools and liquid chromatography and electrochemistry instruments
Slide 14: Scientific and Professional Depth
Scientific and Professional Depth BASi’s pool of scientific and professional talent will enable future growth. Of 240 total employees, there are: – 25 Ph.D s in various sciences – 1 Doctor of Veterinary Medicine – 42 Masters in Sciences and Business – 100 Bachelors in various disciplines – 28 Associ
Slide 15: BASi's Focus and Strategy
BASi’s Focus and Strategy FOCUS Culex franchise for automated dosing and sampling in rodents being extended up to primates New product development Expands service offering Next generation of instrumentation, software and service BASi has taken a leadership position in adopting/adapting Dried Blood S
Slide 16: Financials – Income Statement & Projections Public Comparables Use of Proceeds Management Team Scientific
Financials – Income Statement & Projections Public Comparables Use of Proceeds Management Team Scientific Depth Ownership & Capitalization Table
Slide 17: Financials – Income Statement & Projections
Financials – Income Statement & Projections BASi is poised to have a strong 2011, having recently given guidance that they will become profitable and have sales of $35.1M, an increase of 15% over the previous year. The pace of new contracts is increasing Company believes that the Cash-Flow break-eve
Slide 18: Public Comparables
Public Comparables Relevant public comparables are currently trading at an average of approximately 12.6x TEV/EBITDA and 1.4x TEV/Revenue for the LTM period. Comparable Public Company Analysis: (Contract Research Services -US Exchanges) ($ in millions, except per share data) 3/15/2011 BALANCE SHEET
Slide 19: Financials – Use of Proceeds
Financials – Use of Proceeds The Use of Proceeds in this $5.0M capital raise are to fund the purchase of laboratory equipment and for working capital & general corporate purposes . Use of Proceeds Table Description $ Amount Gross Proceeds $5.0M Purchase of Laboratory Equipment $1.0M Working Capital,
Slide 20: Management Team
Management Team BASi’s seasoned management team has many years of experience in clinical research services and products . Anthony S. Chilton, Ph.D -President & CEO – 30+ years as a scientist and executive in leading life science companies in the UK, Canada and the United States. – Prior to joining t
Slide 21: Management Team (continued)
Management Team (continued ) BASi’s seasoned management team has many years of experience in clinical research services and products . Michael R. Cox – CFO – Former Vice President of Finance and CFO of Integrity Pharmaceutical Corporation, a manufacturer of OB/GYN and Urology healthcare products and
Slide 22: Financials – Ownership & Capitalization Table
Financials – Ownership & Capitalization Table The Company currently has 4,915,318 shares of outstanding common stock OWNERSHIP TABLE Holder Name % of Outstanding Executives and Directors Michael R. Cox (CFO) 1.7% Anthony S. Chilton (President & CEO) 1.4% Other Executive Officers and Directors 1.3% T
Slide 23: Contact Info
Contact Info Bioanalytical Systems Inc. 2701 Kent Avenue West Lafayette, IN Telephone: 765.463.4527 Facsimile: 765.497.1102 Web: www.BASinc.com Bioanalytical Systems Inc. (NASDAQ:BASI) Page 23